Angiotensin II antagonists: Why is there so much excitement?

American Journal of Managed Care

Volumn 4, Issue 7 SUPPL., 1998, Pages

  Hollenberg, Norman K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; BRADYKININ; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; RENIN INHIBITOR; SUBSTANCE P; TACHYKININ;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION;

EID: 0031875222     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Cordero P, Fisher ND, Moore TJ, et al. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. Hypertension 1991;17:510-516.
2. Fisher ND, Allan D, Kifor I, et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension 1994;23:44-51.
3. Fisher ND, Allan DR, Gaboury CL, Hollenberg NK. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition. Hypertension 1995;25:935-939.
4. Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997;30:240-246.
5. Kawabata M, Takabatake T, Ohta H, et al. Effects of an angiotensin II receptor-antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Pressure 1994;3(Suppl 5):117-121.